ESR1 and breast carcinoma: The goal of the current analysis was to compare differences in estrogen receptor (ER)-, proliferation-, and immune-related gene expressions, and somatic mutation patterns and mutation burden between younger (≤50 years of age) and older (≥55 years) patients with HR+/HER2− breast cancer that could explain the chemotherapy benefit in younger women.